Tivicay Pd (dolutegravir) For recalls
The FDA has published 1 recall involving Tivicay Pd (dolutegravir) For since 2024. The latest was reported on 12 Jun 2024. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls1since 2024
Last 12 months0reported
Class I00% of total
Ongoing0latest 12 Jun 2024
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 0 0%Class III 1 100%
Why tivicay pd (dolutegravir) for is recalled
Companies
By year
All tivicay pd (dolutegravir) for recalls, newest first
1 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension recalled | GlaxoSmithKline | Other | Nationwide |
Should you stop taking Tivicay Pd (dolutegravir) For?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.